{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:07:06Z","timestamp":1769818026530,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Paul-Ehrlich-Institut - Bundesinstitut f\u00fcr Impfstoffe und biomedizinische Arzneimittel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Derzeit leiden weltweit mehr als 250\u00a0Mio. Menschen an einer chronischen Infektion mit Hepatitis-B-Virus (CHB). Eine chronische Infektion geht mit einem erh\u00f6hten Risiko der Entwicklung einer Leberfibrose\/-zirrhose und der Entwicklung eines hepatozellul\u00e4ren Karzinoms einher. Derzeit versterben j\u00e4hrlich ca.\u00a00,8\u20131\u00a0Mio. Menschen an den Folgen einer chronischen Infektion. Eine Schwierigkeit bei der Therapie der CHB besteht darin, dass das virale Genom in Form eines Minichroms sehr lange Zeit persistieren kann bzw. dass virale Sequenzen in das Wirtsgenom inserieren k\u00f6nnen. Chronische Infektionen sind h\u00e4ufig durch funktionale Defekte der zellul\u00e4ren Immunantwort, insbesondere der T\u2011Zell-Antwort charakterisiert, was einer Eliminierung HBV-infizierter Zellen entgegensteht.<\/jats:p><jats:p>Immuntherapien zur Heilung der CHB zielen daher darauf ab, die antivirale Funktion der zellul\u00e4ren Immunantwort wiederherzustellen. Im Rahmen dieser \u00dcbersicht sollen verschiedene aktuelle Ans\u00e4tze zur Immuntherapie der CHB beschrieben werden, insbesondere gentechnisch ver\u00e4nderte autologe T\u2011Zellen als m\u00f6gliches Werkzeug zur Therapie der CHB. Weiterhin werden die Modulation von Checkpointinhibitoren der Immunantwort, metabolische T\u2011Zelltherapien und die therapeutische Impfung zur Stimulation der T\u2011Zellantwort als immuntherapeutische Strategien zur Therapie der chronischen HBV-Infektion zusammenfassend dargestellt.<\/jats:p>","DOI":"10.1007\/s00103-020-03223-7","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T22:02:37Z","timestamp":1601416957000},"page":"1357-1364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immuntherapien zur Behandlung der chronischen Hepatitis-B-Virusinfektion \u2013 eine \u00dcbersicht unter besonderer Ber\u00fccksichtigung von CAR-T-Zellen","Immunotherapies for the treatment of chronic hepatitis\u00a0B\u00a0virus infections\u2014an overview with a\u00a0focus on CAR\u00a0T\u00a0cells"],"prefix":"10.1007","volume":"63","author":[{"given":"Zoltan","family":"Ivics","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Amberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Hildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"3223_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479-480","author":"C Seeger","year":"2015","unstructured":"Seeger\u00a0C, Mason\u00a0WS (2015) Molecular biology of hepatitis B virus infection. Virology 479-480:672\u2013686. https:\/\/doi.org\/10.1016\/j.virol.2015.02.031","journal-title":"Virology"},{"issue":"21","key":"3223_CR2","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1007\/s00018-018-2892-y","volume":"75","author":"C Eller","year":"2018","unstructured":"Eller\u00a0C, Heydmann\u00a0L, Colpitts\u00a0CC, Verrier\u00a0ER, Schuster\u00a0C, Baumert\u00a0TF (2018) The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. Cell Mol Life Sci 75(21):3895\u20133905. https:\/\/doi.org\/10.1007\/s00018-018-2892-y","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"3223_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41426-018-0137-7","volume":"7","author":"Y Yu","year":"2018","unstructured":"Yu\u00a0Y, Li\u00a0S, Liang\u00a0W (2018) Bona fide receptor for hepatitis B and D viral infections: mechanism, research models and molecular drug targets. Emerg Microbes Infect 7(1):134. https:\/\/doi.org\/10.1038\/s41426-018-0137-7","journal-title":"Emerg Microbes Infect"},{"key":"3223_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coviro.2018.04.004","volume":"30","author":"T Tu","year":"2018","unstructured":"Tu\u00a0T, Urban\u00a0S (2018) Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Curr Opin Virol 30:68\u201379. https:\/\/doi.org\/10.1016\/j.coviro.2018.04.004","journal-title":"Curr Opin Virol"},{"key":"3223_CR5","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.antiviral.2020.104824","volume":"180","author":"Y Xia","year":"2020","unstructured":"Xia\u00a0Y, Guo\u00a0H (2020) Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res 180:104824. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104824","journal-title":"Antiviral Res"},{"issue":"3","key":"3223_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/BF01703079","volume":"8","author":"CT Bock","year":"1994","unstructured":"Bock\u00a0CT, Schranz\u00a0P, Schr\u00f6der\u00a0CH, Zentgraf\u00a0H (1994) Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 8(3):215\u2013229. https:\/\/doi.org\/10.1007\/BF01703079","journal-title":"Virus Genes"},{"issue":"12","key":"3223_CR7","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","volume":"64","author":"M Nassal","year":"2015","unstructured":"Nassal\u00a0M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a\u00a0cure of chronic hepatitis B. Gut 64(12):1972\u20131984. https:\/\/doi.org\/10.1136\/gutjnl-2015-309809","journal-title":"Gut"},{"key":"3223_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-981-13-9151-4_3","volume":"1179","author":"CE Oropeza","year":"2020","unstructured":"Oropeza\u00a0CE, Tarnow\u00a0G, Sridhar\u00a0A, Taha\u00a0TY, Shalaby\u00a0RE, McLachlan\u00a0A (2020) The regulation of HBV transcription and replication. Adv Exp Med Biol 1179:39\u201369. https:\/\/doi.org\/10.1007\/978-981-13-9151-4_3","journal-title":"Adv Exp Med Biol"},{"key":"3223_CR9","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"M-F Yuen","year":"2018","unstructured":"Yuen\u00a0M\u2011F, Chen\u00a0D\u2011S, Dusheiko\u00a0GM et al (2018) Hepatitis B virus infection. Nat Rev Dis Primers 4:18035. https:\/\/doi.org\/10.1038\/nrdp.2018.35","journal-title":"Nat Rev Dis Primers"},{"key":"3223_CR10","volume-title":"World Health Organization (WHO): Hepatitis B","author":"WHO","year":"2020","unstructured":"WHO (2020) World Health Organization (WHO): Hepatitis B"},{"issue":"1","key":"3223_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","volume":"26","author":"K-N Tsai","year":"2018","unstructured":"Tsai\u00a0K\u2011N, Kuo\u00a0C\u2011F, Ou\u00a0J\u2011HJ (2018) Mechanisms of hepatitis B virus persistence. Trends Microbiol 26(1):33\u201342. https:\/\/doi.org\/10.1016\/j.tim.2017.07.006","journal-title":"Trends Microbiol"},{"key":"3223_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coviro.2018.09.003","volume":"32","author":"MM Gaglia","year":"2018","unstructured":"Gaglia\u00a0MM, Munger\u00a0K (2018) More than just oncogenes: mechanisms of tumorigenesis by human viruses. Curr Opin Virol 32:48\u201359. https:\/\/doi.org\/10.1016\/j.coviro.2018.09.003","journal-title":"Curr Opin Virol"},{"issue":"11","key":"3223_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning\u00a0GC, Zoulim\u00a0F, Hou\u00a0J, Bertoletti\u00a0A (2019) Therapeutic strategies for hepatitis B virus infection: towards a\u00a0cure. Nat Rev Drug Discov 18(11):827\u2013844. https:\/\/doi.org\/10.1038\/s41573-019-0037-0","journal-title":"Nat Rev Drug Discov"},{"key":"3223_CR14","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.3389\/fimmu.2019.02240","volume":"10","author":"K Heim","year":"2019","unstructured":"Heim\u00a0K, Neumann-Haefelin\u00a0C, Thimme\u00a0R, Hofmann\u00a0M (2019) Heterogeneity of HBV-specific CD8+ T\u2011cell failure: implications for immunotherapy. Front Immunol 10:2240. https:\/\/doi.org\/10.3389\/fimmu.2019.02240","journal-title":"Front Immunol"},{"issue":"7","key":"3223_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.3251","volume":"19","author":"B Rehermann","year":"2013","unstructured":"Rehermann\u00a0B (2013) Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19(7):859\u2013868. https:\/\/doi.org\/10.1038\/nm.3251","journal-title":"Nat Med"},{"key":"3223_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","volume":"11","author":"P Fisicaro","year":"2020","unstructured":"Fisicaro\u00a0P, Barili\u00a0V, Rossi\u00a0M et\u00a0al (2020) Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front Immunol 11:849. https:\/\/doi.org\/10.3389\/fimmu.2020.00849","journal-title":"Front Immunol"},{"key":"3223_CR17","doi-asserted-by":"publisher","first-page":"104748","DOI":"10.1016\/j.antiviral.2020.104748","volume":"176","author":"AT Tan","year":"2020","unstructured":"Tan\u00a0AT, Schreiber\u00a0S (2020) Adoptive T\u2011cell therapy for HBV-associated HCC and HBV infection. Antiviral Res 176:104748. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104748","journal-title":"Antiviral Res"},{"issue":"5","key":"3223_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.5009\/gnl17233","volume":"12","author":"A Bertoletti","year":"2018","unstructured":"Bertoletti\u00a0A, Le Bert\u00a0N (2018) Immunotherapy for chronic hepatitis B virus infection. Gut Liver 12(5):497\u2013507. https:\/\/doi.org\/10.5009\/gnl17233","journal-title":"Gut Liver"},{"key":"3223_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112754","author":"C Boni","year":"2019","unstructured":"Boni\u00a0C, Barili\u00a0V, Acerbi\u00a0G et al (2019) HBV immune-therapy: from molecular mechanisms to clinical applications. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20112754","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3223_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain\u00a0M, Brentjens\u00a0R, Rivi\u00e8re\u00a0I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388\u2013398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548","journal-title":"Cancer Discov"},{"issue":"8","key":"3223_CR21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava\u00a0S, Riddell\u00a0SR (2015) Engineering CAR\u2011T cells: design concepts. Trends Immunol 36(8):494\u2013502. https:\/\/doi.org\/10.1016\/j.it.2015.06.004","journal-title":"Trends Immunol"},{"issue":"6","key":"3223_CR22","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle\u00a0CJ, Hanafi\u00a0L\u2011A, Berger\u00a0C et al (2016) CD19 CAR\u2011T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J\u00a0Clin Invest 126(6):2123\u20132138. https:\/\/doi.org\/10.1172\/JCI85309","journal-title":"J Clin Invest"},{"issue":"355","key":"3223_CR23","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle\u00a0CJ, Hanafi\u00a0L\u2011A, Berger\u00a0C et al (2016) Immunotherapy of non-Hodgkin\u2019s lymphoma with a\u00a0defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8(355):355ra116. https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621","journal-title":"Sci Transl Med"},{"issue":"8","key":"3223_CR24","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/17474086.2016.1203251","volume":"9","author":"CJ Turtle","year":"2016","unstructured":"Turtle\u00a0CJ, Maloney\u00a0DG (2016) Clinical trials of CD19-targeted CAR-modified T cell therapy; a\u00a0complex and varied landscape. Expert Rev Hematol 9(8):719\u2013721. https:\/\/doi.org\/10.1080\/17474086.2016.1203251","journal-title":"Expert Rev Hematol"},{"issue":"16","key":"3223_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude\u00a0SL, Frey\u00a0N, Shaw\u00a0PA et\u00a0al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N\u00a0Engl J Med 371(16):1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"issue":"224","key":"3223_CR26","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila\u00a0ML, Riviere\u00a0I, Wang\u00a0X et\u00a0al (2014) Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25. https:\/\/doi.org\/10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"},{"issue":"9967","key":"3223_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee\u00a0DW, Kochenderfer\u00a0JN, Stetler-Stevenson\u00a0M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a\u00a0phase 1 dose-escalation trial. Lancet 385(9967):517\u2013528. https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3","journal-title":"Lancet"},{"issue":"26","key":"3223_CR28","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle\u00a0CJ, Hay\u00a0KA, Hanafi\u00a0L\u2011A et al (2017) Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J\u00a0Clin Oncol 35(26):3010\u20133020. https:\/\/doi.org\/10.1200\/JCO.2017.72.8519","journal-title":"J Clin Oncol"},{"issue":"21","key":"3223_CR29","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay\u00a0KA, Hanafi\u00a0L\u2011A, Li\u00a0D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T\u2011cell therapy. Blood 130(21):2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"issue":"12","key":"3223_CR30","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust\u00a0J, Hay\u00a0KA, Hanafi\u00a0L\u2011A et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR\u2011T cells. Cancer Discov 7(12):1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698","journal-title":"Cancer Discov"},{"issue":"11","key":"3223_CR31","doi-asserted-by":"publisher","first-page":"e970027","DOI":"10.4161\/21624011.2014.970027","volume":"3","author":"GL Beatty","year":"2014","unstructured":"Beatty\u00a0GL, Moon\u00a0EK (2014) Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. OncoImmunology 3(11):e970027. https:\/\/doi.org\/10.4161\/21624011.2014.970027","journal-title":"OncoImmunology"},{"issue":"5","key":"3223_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0000000000000126","volume":"39","author":"HG Caruso","year":"2016","unstructured":"Caruso\u00a0HG, Torikai\u00a0H, Zhang\u00a0L et al (2016) Redirecting T\u2011cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptor. J\u00a0Immunother 39(5):205\u2013217. https:\/\/doi.org\/10.1097\/CJI.0000000000000126","journal-title":"J Immunother"},{"key":"3223_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gde.2018.06.003","volume":"52","author":"M Hudecek","year":"2018","unstructured":"Hudecek\u00a0M, Ivics\u00a0Z (2018) Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. Curr Opin Genet Dev 52:100\u2013108. https:\/\/doi.org\/10.1016\/j.gde.2018.06.003","journal-title":"Curr Opin Genet Dev"},{"issue":"4","key":"3223_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/10409238.2017.1304354","volume":"52","author":"M Hudecek","year":"2017","unstructured":"Hudecek\u00a0M, Izsv\u00e1k\u00a0Z, Johnen\u00a0S, Renner\u00a0M, Thumann\u00a0G, Ivics\u00a0Z (2017) Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol 52(4):355\u2013380. https:\/\/doi.org\/10.1080\/10409238.2017.1304354","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"11","key":"3223_CR35","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.tig.2017.08.008","volume":"33","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei\u00a0P, Izsv\u00e1k\u00a0Z, Narayanavari\u00a0SA, Singh\u00a0H, Ivics\u00a0Z (2017) Gene therapy with the Sleeping Beauty transposon system. Trends Genet 33(11):852\u2013870. https:\/\/doi.org\/10.1016\/j.tig.2017.08.008","journal-title":"Trends Genet"},{"issue":"4","key":"3223_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/s0092-8674(00)80436-5","volume":"91","author":"Z Ivics","year":"1997","unstructured":"Ivics\u00a0Z, Hackett\u00a0PB, Plasterk\u00a0RH, Izsv\u00e1k\u00a0Z (1997) Molecular reconstruction of Sleeping Beauty, a\u00a0Tc1-like transposon from fish, and its transposition in human cells. Cell 91(4):501\u2013510. https:\/\/doi.org\/10.1016\/s0092-8674(00)80436-5","journal-title":"Cell"},{"issue":"8","key":"3223_CR37","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","volume":"68","author":"H Singh","year":"2008","unstructured":"Singh\u00a0H, Manuri\u00a0PR, Olivares\u00a0S et al (2008) Redirecting specificity of T\u2011cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68(8):2961\u20132971. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5600","journal-title":"Cancer Res"},{"issue":"7","key":"3223_CR38","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1172\/JCI120228","volume":"129","author":"K Wisskirchen","year":"2019","unstructured":"Wisskirchen\u00a0K, Kah\u00a0J, Malo\u00a0A et\u00a0al (2019) T cell receptor grafting allows virological control of Hepatitis B virus infection. J\u00a0Clin Invest 129(7):2932\u20132945. https:\/\/doi.org\/10.1172\/JCI120228","journal-title":"J Clin Invest"},{"issue":"1","key":"3223_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jhep.2010.10.025","volume":"55","author":"AJ Gehring","year":"2011","unstructured":"Gehring\u00a0AJ, Xue\u00a0S\u2011A, Ho\u00a0ZZ et al (2011) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J\u00a0Hepatol 55(1):103\u2013110. https:\/\/doi.org\/10.1016\/j.jhep.2010.10.025","journal-title":"J Hepatol"},{"issue":"1","key":"3223_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.gastro.2018.03.027","volume":"155","author":"S Koh","year":"2018","unstructured":"Koh\u00a0S, Kah\u00a0J, Tham\u00a0CYL et al (2018) Nonlytic lymphocytes engineered to express virus-specific T\u2011cell receptors limit HBV infection by activating APOBEC3. Gastroenterology 155(1):180\u2013193.e6. https:\/\/doi.org\/10.1053\/j.gastro.2018.03.027","journal-title":"Gastroenterology"},{"issue":"2","key":"3223_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2013.04.047","volume":"145","author":"K Krebs","year":"2013","unstructured":"Krebs\u00a0K, B\u00f6ttinger\u00a0N, Huang\u00a0L\u2011R et al (2013) T cells expressing a\u00a0chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145(2):456\u2013465. https:\/\/doi.org\/10.1053\/j.gastro.2013.04.047","journal-title":"Gastroenterology"},{"issue":"5","key":"3223_CR42","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","volume":"71","author":"E Gane","year":"2019","unstructured":"Gane\u00a0E, Verdon\u00a0DJ, Brooks\u00a0AE et al (2019) Anti-PD\u20111 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J\u00a0Hepatol 71(5):900\u2013907. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.028","journal-title":"J Hepatol"},{"issue":"1 Suppl","key":"3223_CR43","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","volume":"64","author":"D Durantel","year":"2016","unstructured":"Durantel\u00a0D, Zoulim\u00a0F (2016) New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J\u00a0Hepatol 64(1 Suppl):S117\u2013S131. https:\/\/doi.org\/10.1016\/j.jhep.2016.02.016","journal-title":"J Hepatol"},{"key":"3223_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3389\/fimmu.2020.00401","volume":"11","author":"RC Hoogeveen","year":"2020","unstructured":"Hoogeveen\u00a0RC, Boonstra\u00a0A (2020) Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection. Front Immunol 11:401. https:\/\/doi.org\/10.3389\/fimmu.2020.00401","journal-title":"Front Immunol"},{"issue":"3","key":"3223_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nm.4275","volume":"23","author":"P Fisicaro","year":"2017","unstructured":"Fisicaro\u00a0P, Barili\u00a0V, Montanini\u00a0B et al (2017) Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med 23(3):327\u2013336. https:\/\/doi.org\/10.1038\/nm.4275","journal-title":"Nat Med"},{"issue":"8","key":"3223_CR46","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.4049\/jimmunol.1203449","volume":"191","author":"Z Zeng","year":"2013","unstructured":"Zeng\u00a0Z, Kong\u00a0X, Li\u00a0F, Wei\u00a0H, Sun\u00a0R, Tian\u00a0Z (2013) IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a\u00a0mouse model of hepatitis B virus carrier. J\u00a0Immunol 191(8):4184\u20134193. https:\/\/doi.org\/10.4049\/jimmunol.1203449","journal-title":"J Immunol"},{"issue":"4","key":"3223_CR47","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/hep.29239","volume":"66","author":"Y Bian","year":"2017","unstructured":"Bian\u00a0Y, Zhang\u00a0Z, Sun\u00a0Z et\u00a0al (2017) Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology 66(4):1067\u20131082. https:\/\/doi.org\/10.1002\/hep.29239","journal-title":"Hepatology"},{"issue":"35","key":"3223_CR48","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2015.03.079","volume":"33","author":"J Li","year":"2015","unstructured":"Li\u00a0J, Ge\u00a0J, Ren\u00a0S et\u00a0al (2015) Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a\u00a0novel therapeutic vaccine for chronic hepatitis B infection. Vaccine 33(35):4247\u20134254. https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.079","journal-title":"Vaccine"},{"key":"3223_CR49","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3389\/fimmu.2019.03127","volume":"10","author":"Z Meng","year":"2019","unstructured":"Meng\u00a0Z, Chen\u00a0Y, Lu\u00a0M (2019) Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection. Front Immunol 10:3127. https:\/\/doi.org\/10.3389\/fimmu.2019.03127","journal-title":"Front Immunol"},{"issue":"15","key":"3223_CR50","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1016\/j.vaccine.2020.02.063","volume":"38","author":"T Zahn","year":"2020","unstructured":"Zahn\u00a0T, Akhras\u00a0S, Spengler\u00a0C, Murra\u00a0RO, Holzhauser\u00a0T, Hildt\u00a0E (2020) A new approach for therapeutic vaccination against chronic HBV infections. Vaccine 38(15):3105\u20133120. https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.063","journal-title":"Vaccine"},{"key":"3223_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020216","author":"S Ezzikouri","year":"2020","unstructured":"Ezzikouri\u00a0S, Kayesh\u00a0MEH, Benjelloun\u00a0S, Kohara\u00a0M, Tsukiyama-Kohara\u00a0K (2020) Targeting host innate and adaptive immunity to achieve the functional cure of chronic hepatitis B. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines8020216","journal-title":"Vaccines (Basel)"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-020-03223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-020-03223-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-020-03223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:05:22Z","timestamp":1632870322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-020-03223-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["3223"],"URL":"https:\/\/doi.org\/10.1007\/s00103-020-03223-7","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Z.\u00a0Ivics, M.\u00a0Amberger, T.\u00a0Zahn und E.\u00a0Hildt geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Bei der Abfassung dieser Arbeit wurden alle ethischen Richtlinien eingehalten.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}